Regeneron Beats EPS and Revenue Estimates

Tarrytown, NY - March 21, 2020 - This week Regeneron Pharmaceuticals announced clinical trials of arthritis drug Kevzara to treat Covid-19; they hope to trial an antibody cocktail therapy by summer.
Marianne Campolongo /

Biotechnical company Regeneron (NASDAQ: REGN) announced earnings today for the fourth quarter 2020 and beat analysts’ estimates for both revenue and earnings per share. The company also said it had signed an agreement with the U.S. government to purchase up to 1.25 million additional doses of REGEN-COV, the antibody cocktail it produces and which received Food and Drug Administration emergency use authorization.

See: COVID Antibody Treatments Show Potential as Vaccine Roll-Out Stumbles; Regeneron Stock Soars
Find: As Vaccines and 5G Come to Pharmacies Near You, Walgreens and Verizon Are Stocks to Watch

Last week, the company announced that the antibody cocktail “successfully neutralizes” both the U.K. variant (B.1.1.7) and South Africa variant (B.1.351) of COVID.

The company reported EPS $9.53 and revenue of  $2.42 billion, a 30% increase compared to the fourth quarter of 2019, compared to consensus EPS estimate of $8.29 and consensus revenue estimate of $2.4 billion, according to Seeking Alpha.

“In 2020, the Regeneron team rapidly mobilized our significant scientific, development, manufacturing, and operational capabilities to bring our monoclonal antibody cocktail, REGEN-COV, to patients with COVID-19 through an Emergency Use Authorization,” Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron said in the earnings statement, adding that it will continue its work on COVID in 2021.

Make Your Money Work Better for You

See: 25 Pandemic-Proof Stocks
Find: 25 Companies Making the Most Money From Coronavirus

REGEN-COV received the FDA emergency use authorization in November 2020. The drug is authorized for the treatment of “mild to moderate COVID-19 in certain patients at high risk for progressing to severe COVID-19 and/or hospitalization,” according to the statement. The company adds that net product sales of REGEN-COV were $146 million in the fourth quarter of 2020 and $186 million for the full year of 2020.

In January, the company signed a second agreement with the U.S. government, in which it will acquire up to 1.25 million additional doses, resulting in payments to the company of up to $2.62, according to the statement.

“In 2020, Regeneron delivered double-digit top- and bottom-line growth and significant shareholder value despite the unprecedented circumstances of a global pandemic,” according to Robert E. Landry, Regeneron’s executive vice president of finance and chief financial officer. “As we look ahead into 2021 and beyond, our business momentum and strong balance sheet give us confidence as we invest in R&D for long-term growth and execute on our capital allocation priorities.”

More From GOBankingRates:

Make Your Money Work Better for You

Share this article:

facebook sharing button
twitter sharing button
linkedin sharing button
email sharing button
Make Your Money Work Better for You

About the Author

Yaël Bizouati-Kennedy is a full-time financial journalist and has written for several publications, including Dow Jones, The Financial Times Group, Bloomberg and Business Insider. She also worked as a vice president/senior content writer for major NYC-based financial companies, including New York Life and MSCI. Yaël is now freelancing and most recently, she co-authored  the book “Blockchain for Medical Research: Accelerating Trust in Healthcare,” with Dr. Sean Manion. (CRC Press, April 2020) She holds two master’s degrees, including one in Journalism from New York University and one in Russian Studies from Université Toulouse-Jean Jaurès, France.
Learn More


See Today's Best
Banking Offers